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Abstract
Therapeutic strategies to correct an excessive immune response to pathogenic infec-
tion is investigated as an optimal control problem. The control problem is formulated
around a four dimensional mathematical model describing the inflammatory response
to a pathogenic insult with two therapeutic control inputs which have either a direct
pro- or anti-inflammatory effect in the given system. We use Pontryagin’s maximum
principle and discuss necessary optimality conditions. We consider both an L1 type
objective functional as well as an L2 type objective. For the former, the presence of
singular control will be addressed. For each case, numerical simulations using a nonlin-
ear programming optimization solver to acquire different drug treatment strategies are
presented and discussed. The results provide insight for possible treatment strategies
and the methods could be a relevant tool for future practice to assist in better prediction
of clinical outcomes and subsequently better treatment for patients.
Keywords: Optimal control, Biological system, Inflammatory response, Sepsis
1. Introduction
The immune response is a complex mechanism triggered in an organism as a result
of biological or physical stress, such as the presence of a foreign body (pathogenic infec-
tion) or trauma. The natural behavior of an organism to respond to these phenomena
is through stress adaptation by trying to eliminate the invading pathogen threat in case
of an infection while also promoting tissue repair due to the self-harming effects of in-
flammation. However, an excessive and dysregulated inflammatory response may lead to
systemic inflammatory response syndrome (SIRS) and sepsis, resulting in tissue damage,
organ dysfunction or even death. According to [1], the overall mortality is approximately
30%, rising to 40% in the elderly and is 50% or greater in patients with severe SIRS and
sepsis.
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With the withdrawal of previously approved drugs to treat sepsis ([2]) and the ac-
knowledgment that potential therapies for sepsis such as anti-tumor necrosis factor-α
appear to require accurate timing ([3], [4]), identifying effective therapies and patient-
specific protocols for curbing sepsis is increasingly important. Using computational tools
and methodologies is one means by which to explore this and offer insight. In particular,
applying automatic control for biomedical therapeutic intervention has recently gained
interest in such areas as glucose control for diabetes or in critically ill patients and for
anesthesia depth control, as seen for example, in [5], [6], [7], [8], and the references
therein. The use of optimal control theory for biomedical applications can be seen in [9],
[10], and [11] for example; and, more recently, the use of model predictive control (MPC)
in [12] and [13] which used the same mathematical model as used herein. MPC was also
used in [14] and [15] for diabetes treatment strategies and [16] for an application to a
multi-compartment respiratory system.
In the cases where MPC is used, an optimal control problem is essentially solved for
each specified time interval over the duration of the time span, as though implementing
the control measures in real time (i.e. online) as the response is evolving. In this work,
we investigate the offline strategy that solves the control problem for the entire time
period of interest: from the start of treatment till the end of the observation period.
Within this strategy, we explore differences in the form of the objective function used as
well as determine the effectiveness of the identified treatment protocol.
As in our prior work ([17], [18], [12], [13]), we utilize a phenomenological ordinary
differential equations model of the system inflammatory response to pathogenic infection
developed in [19] (see also [20]). This model provides a dynamical system with rich
behavior that is ideal for testing various theoretical control strategies. A summary of its
important features are as follows:
• This model is based on the early non-specific protective mechanism, namely, the
innate immune response, in contrast to the mechanisms of adaptive immunity. It
is a lumped variable/lumped parameter model, representing an abstract view of
the dynamics of an acute inflammatory response and implicitly considering affects
of typical intervention strategies such as antibiotic use or the administration of
resuscitating fluids;
• An anti-inflammatory mediator is included as a dynamic variable of the model.
This mediator plays an important role in directly mitigating inflammation as a
way to prevent excessive tissue damage caused by severe inflammation; and
• The model’s biological relevance has been confirmed through its good qualitative
reproduction of severe systemic inflammatory states as observed in a clinical setting.
In this paper, we explore the use of optimal control theory to derive an immune
control strategy for the chosen model consisting of manipulating the pro- and/or anti-
inflammatory mediator in order to reestablish the healthy equilibrium of the virtual
patient. Note that the model does not target a specific pathogen and the control doses
represent concentrations of inflammatory mediators with idealized effect on the system.
Even so, the careful balance required for effective treatment is evident. For instance, a
large dose of pro-inflammatory therapy, while aiming to eliminate the pathogen, would
also pose a risk in causing possibly irreparable damage to organs. Similarly, using a
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large amount of anti-inflammatory therapy could suppress the negative effects of the
inflammatory-damage feedback loop and consequently preserve organ health; however,
this intervention may also suppress the positive effects of inflammation in controlling
pathogen which may then be uninhibited to rapidly grow. The dual objectives to
eliminate pathogen but also minimize damage via the administration of pro- and anti-
inflammatory mediators, respectively, necessitates the use of a control algorithm in order
to find a suitable balance that produces the desired outcome: a healthy patient.
In [18] and [17] the necessary conditions of Pontryagin’s maximum principle [21] were
used in order to formulate a two point boundary value problem (TPBVP) which was
solved numerically with the forward-backward sweep method [22] (indirect method). In
the current work, we choose to use a direct approach to the numerical solutions that relies
on approximating the original optimal control problem by first discretizing the state and
control history and then solving it using nonlinear programming (NL). Further details
about the solver used will be given in section 4. Constraints are handled more easily in the
direct method than in the indirect method where one must derive adjoint equations along
with the transversality and optimality conditions before the TPBVP problem can be
solved. Furthermore, in the indirect method, the presence of state inequality constraints
requires a priori knowledge of the number and duration of constrained arcs which is
unknown beforehand [23].
We compare the results of using a quadratic or L2 objective function versus a linear
or L1 one. The use of a quadratic cost to derive the optimal control can be explained
by two important facts. First the corresponding Hamiltonian will be strictly convex
in the control with a unique minimum, and second, the mathematical problem is more
straightforward to solve. Alternatively, using an L1 or linear objective avoids distortion
due to the square used in the L2 form which puts a small penalty on lower doses and
therefore, potentially biases the real effect of the control in the cost function [24]. Also,
the use of an L1 objective often results in “bang-bang” controls, meaning the control is
applied at either its maximum level or its minimum level, which provide simple dosing
protocols whose amounts do not vary greatly over time. In this respect, such controls
are more analogous to how medical treatments are administered in practice and are
considered natural choices as candidates for optimality [25].
The simulation results presented herein show some similarities when compared to [18]
and [17], in that the optimal control doses follow a certain strategy whether considering
a quadratic or a linear objective. As will be noted later, the optimal inputs for a virtual
patient whose inflammatory mediators are elevated above some prescribed threshold
are characterized by a bolus of pro-inflammatory therapy followed just after by anti-
inflammatory therapy, consistent with earlier findings in [12].
The paper is organized as follows. Sections 2 and 3 respectively explain the math-
ematical model and the optimal control problem. A brief background regarding the
numerical solver (PSOPT) is provided in Section 4 together with the numerical results
for both the quadratic and linear cases. Suggestions for future extensions to this work
are discussed in section 5.
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2. Immune response model
We consider the mathematical model describing the inflammatory response for a
host-pathogen interaction as proposed in [19] and consider the model as representing the
immune dynamics of a virtual patient. There are four system states of the model:
• P : the bacterial pathogen population that initiates the inflammatory response;
• N : combined collection of early pro-inflammatory mediators such as activated
phagocytes (e.g. neutrophils) and the pro-inflammatory cytokines they produce;
• D : a marker of global tissue damage which incites further inflammation and which
is useful for determining response outcomes; and
• Ca: combined collection of anti-inflammatory mediators, such as cortisol, Interleukin-
10 (IL-10) and Transforming Growth Factor-beta (TGF-β).
In [12] it was first proposed to include non-negative, time-varying inputs to account
for therapeutic controls in this model. Here, we denote these as follows:
• up(t): a pro-inflammatory enhancer that provides direct input into the N equation;
and
• ua(t): an anti-inflammatory enhancer that provides direct input into the Ca equa-
tion.
The dynamic equations describing the interactions of the four system variables, P ,
N , D, and Ca, are governed by various rate constants or parameters whose numerical
values can be found in [19]. As was done in [12], we consider different sets of parameter
values to represent different virtual patients’ inflammatory responses. We refer to the
values given in [19] as the reference set of parameter values.
The diagram in Figure 1 characterizes the different interactions that exist between
the states of the inflammatory model. A solid line with an arrow head indicates an
up-regulation, whereas a dashed line with circular head indicates inhibition or downreg-
ulation of a process. For instance, early pro-inflammatory mediators, N , respond to the
presence of pathogen, P , by initiating self-recruitment of additional inflammatory medi-
ators and N is therefore upregulated by the interaction with P to attempt to efficiently
eliminate the pathogen. The self up-regulation that exists for P is due to replication.
Furthermore, N suppresses P by eliminating it at some rate when they interact; how-
ever, the inflammation caused by N results in tissue damage, D, which can provide a
positive feedback into the early inflammatory mediators depending on their intensity. To
balance this, anti-inflammatory mediators (e.g., cortisol, IL-10, TGF-β) can mitigate the
inflammation and its harmful effect by suppressing the response by N and the effects
of D in various ways. The ordinary differential equations modeling these interactions is
given by Equations (1) - (4):
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Figure 1: Diagram of natural and enhanced immune dynamics in response to pathogenic stimulus.
P : replicating pathogen, N : early pro-inflammatory immune mediators, D: marker of tissue dam-
age/dysfunction caused by inflammatory response, Ca: inhibitory anti-inflammatory mediators, ua and
up: time-varying input controls for the anti- and pro-inflammatory therapy, respectively. Solid lines
with arrow heads and dashed lines with nodes/circular heads represent upregulation and inhibition,
respectively.
P˙ (t) = kpgP (t)
(
1− P (t)
p∞
)
− kpmsmP (t)
µm + kmpP (t)
− kpnF (N(t))P (t) (1)
N˙(t) =
snrR(P (t), N(t), D(t))
µnr +R(P (t), N(t), D(t))
− µnN(t) + up(t) (2)
D˙(t) = kdn
F (N(t))6
x6dn + F (N(t))
6
− µdD(t) (3)
C˙a(t) = sc + kcn
F (N(t) + kcndD(t))
1 + F (N(t) + kcndD(t))
− µcCa(t) + ua(t), (4)
where
R(P,N,D) = F (knpP (t) + knnN(t) + kndD(t)) and
F (x) =
x
1 +
(
Ca(t)
c∞
)2 .
As explained in [19], F (x) represent a Hill function of order 6 that models the impact
of activated phagocytes and their by-products (N) on the creation of damaged tissue.
Tissue damage (D) increases in a switch-like sigmoidal fashion as N increases, so that
it takes sufficiently high levels of N to incite a moderate increase in damage and that
the increase in damage saturates with sufficiently elevated and sustained N levels. The
coefficient (exponent) 6 was chosen, therefore, to model this aspect which ensured that
the healthy equilibrium had a reasonable basin of attraction for the N/D system.
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The model was formulated to represent a most abstract form of the complex pro-
cesses involved in the systemic inflammatory response. Hence, the variables N and Ca
represent multiple mediators with similar inflammatory characteristics, and D is an ab-
stract representation of tissue damage. This abstraction reduces the description to four
essential variables which also allows for tractable mathematical analysis. Therefore the
units of these variables are in arbitrary units of N -units, Ca-units, D-units, since they
represent various types of cells and thus, they qualitatively rather than quantitatively
describe the response of the inflammatory mediators and by-products each represents.
Pathogen, P , units are more closely related to numbers of pathogens or colony forming
units (CFU), but abstract units P -units are simply used as well and this population is
scaled by 106/cc. More details about the model development can be found in [19].
The Ca variable maintains a small positive background level when the system is in
steady state in the presence of no pathogen insult. Following the setup used in [12], the
reference parameter value for Ca(0) is set to 0.125 and virtual patients have a value that
is ±25% of the reference value. In addition, five other parameters as well as the initial
conditions for P and Ca are made to have differing (positive) values from the reference
set to distinguish one virtual patient from another and from the virtual patient having
the reference set of parameters.
At the end of 168 hours1, a healthy outcome of a virtual patient’s inflammatory re-
sponse given a particular initial pathogen is defined as the ending state in which D = 0,
P = 0, N = 0, and Ca is at its initial background level. On the other hand, a patient is
considered to have an unhealthy outcome if the ending state has either P = 0 with all
other variable values elevated above their background non-infection steady state values
(aseptic death outcome) or when P is also elevated along with the other variables (septic
death outcome). The fact that a virtual patient may, or may not, return to a healthy state
depends on the parameter values and initial condition. When inflammatory levels of a
response are deemed excessive (i.e. N(t) > 0.5 in this work), then intervention becomes
necessary to stabilize the patient to his healthy equilibrium (i.e. to homeostasis). In
the work here, we consider two virtual patients whose inflammatory response outcomes
are septic death and aseptic death, respectively, in the absence of intervention measures.
Below, we summarize for each virtual patient the corresponding parameter values used
as well as the initial conditions which represents the state of the patient’s inflamma-
tory response some past time when the initial infection occurred, and the inflammatory
response has become elevated enough to warrant therapeutic intervention.
• Baseline Patient
– Healthy equilibrium: P (0) = 0, N(0) = 0, D(0) = 0, Ca(0) = 0.125.
– Parameter values of the reference patient: kpg = 0.6, kcn = 0.04, knd = 0.02,
knp = 0.1, kcnd = 48, knn = 0.01.
1168 hours, which is equivalent to one week, is considered to be a clinically relevant time period over
which to observe a patient experiencing a severe inflammatory response and when outcome would most
likely could be determined. Our results match this time frame, as for example, from Figure 2 one can
see that by 168h it is relatively clear to determine to which equilibrium the time courses are converging,
whether septic death or the aseptic death region.
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Figure 2: Time courses of system states for natural (open loop) response for virtual patient 1 (solid
curves), resulting in a (septic death outcome) and for virtual patient 2 (dashed curves), resulting in an
(aseptic death outcome.)
• Patient 1 (septic death outcome)
– Initial conditions: P (0) = 0.5360, N(0) = 0.0660, D(0) = 0.0477, Ca(0) =
0.1635.
– Parameter values differing from reference set: kpg = 0.5846, kcn = 0.0409,
knd = 0.0242, knp = 0.1211, kcnd = 49.1243, knn = 0.012.
• Patient 2 (aseptic death outcome)
– Initial conditions: P (0) = 1.0017, N(0) = 0.0711, D(0) = 0.0732, Ca(0) =
0.1314.
– Parameter values differing from reference set: kpg = 0.4746, kcn = 0.0386,
knd = 0.0223, knp = 0.1116, kcnd = 46.3367, knn = 0.0112.
The differential equations model using the parameter values and initial conditions cor-
responding to each virtual patient is numerically solved and the resulting time courses
for each are shown in Figure 2. Solid curves display the solution time courses for pa-
tient 1 and dashed curves are for patient 2. As illustrated, in the absence of any control
measures, each virtual patient’s trajectory evolves toward either of the final unhealthy
steady states. Next, we demonstrate how interventions via positive inputs into the system
can redirect trajectories away from the unhealthy steady states and toward the healthy
steady state.
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3. The Optimal Control Problems
We consider optimal control problems in which the controls enter linearly into the
system. After algebraically rearranging the expressions in equations (1)-(4) and renaming
the resulting parameter expressions from a to w as shown in Table 1, the model system
with controls can now be written as:

P˙
N˙
D˙
C˙a
 = f(x) + g(x)u =

aP − bP 2 − cPd+eP − zg+C2aPN
hP+iN+jD
kP+lN+mD+nC2a+o
− pN
qN6
(r+sC2a)
6+tN6 − µdD
sc +
uN+vD
g+C2a+gN+wD
− µcCa
+

0 0
1 0
0 0
0 1
(upua
)
(5)
a = kpg e = kmp i = c
2
∞snrknn m = c
2
∞knd q = c
12
∞kdn
b =
kpg
P∞
z = kpnc
2
∞ j = c
2
∞snrknd s = kdn n = knr
c = kpmsm g = c
2
∞ k = c
2
∞knp o = c
2
∞knr t = c
12
∞
d = km h = c
2
∞snrknp l = c
2
∞knn p = kn u = c
2
∞kcn
v = c2∞kcnkcnd r = c
2
∞kdn w = c
2
∞kcnd
Table 1: Parameters of the algebraically rearranged immune model with control terms as given in (5).
where f(x) and g(x) represent a vector and a matrix, respectively, that can be easily
inferred from equation (5). The state vector is given by x = (P,N,D,Ca)
T and the
control vector by u = (up, ua)
T . The above alternate representation of the system, after
algebraically rearranging the immune model equations, provides a more useful form for
the differentiation that will be carried out below in solving the control problem and allows
a better understanding of the role of each state in the system. Two case studies will be
investigated: an optimal control problem with L1-type objective (linear cost term) versus
one with an L2-type objective (quadratic cost term) in J .
For the quadratic case the objective functional to be minimized is therefore given as
J(up, ua) =
∫ tf
0
a1P (t)
2 + a2N(t)
2 + a3D(t)
2 + a4Ca(t)
2 +B1up(t)
2 +B2ua(t)
2dt (6)
For the linear case, the objective functional is given according to
J(up, ua) =
∫ tf
0
a1P (t) + a2N(t) + a3D(t) + a4Ca(t) +B1up(t) +B2ua(t)dt (7)
The goal here, for both functionals is to determine the optimal control pair u∗p and u
∗
a
such that
J(u∗p, u
∗
a) = min
(up,ua)∈U
J(up, ua) (8)
where the basic control set is
U = {(up, ua) ∈ (L∞(0, tf ))2| 0 ≤ up(t) ≤Mp, 0 ≤ ua(t) ≤Ma, a.e.}
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and other state constraints may be considered later.
Note that during our simulation we also added the final cost term to our objective
functional as φ(x(tf )) = P (tf ) +N(tf ) +D(tf ) +Ca(tf ) for the linear case and similarly
φ(x(tf )) = x(tf )
Tx(tf ) = P
2(tf ) +N
2(tf ) +D
2(tf ) + C
2
a(tf ) for the quadratic one.
The optimal state x∗, although satisfying the equality constraints x˙ = f(x(t), u(t)),
is further constrained by the initial and final boundary condition, or point constraints. In
our case, the initial state is x(0) = (P (0), N(0), D(0), Ca(0)) = (0.536, 0.066, 0.0477, 0.1635)
for patient 1 and (1.0017, 0.0711, 0.0732, 0.1314) for patient 2 and the final state for each
is x(tf ) = (P (tf ), N(tf ), D(tf ), Ca(tf )) = (0, 0, 0, 0.125).
The approach known as the indirect method, used in our previous publications [18, 17],
attempts to preserve the infinite dimensional nature of the problem [26] and uses Pon-
traygin’s maximum principle to solve a TPBVP. The disadvantage of the indirect method
lies in the fact that the boundary problem with the transversality condition is often diffi-
cult to solve, and can become further encumbered in the presence of path constraints. In
this work, we take an approach that finds a finite dimensional representation necessary
to solve the problem. Such approaches are known as direct methods and to achieve this,
we discretize the state and/or control variables and formulate a nonlinear programming
problem (NLP) to solve the optimization problem.
3.1. Existence of an optimal control
Practically, before attempting to numerically find an optimal control solution, it is
interesting to see if an optimal control indeed exists. The existence of an optimal control
for the L1 and L2 objective functional can be obtained from standard results like in
[27, 28] or by using a weak convergence direct approach [29]. These results use the
bounded range of the controls and the states as well as the structure of the ODE system
being linear in the controls. Also the right hand sides of the ODEs are continuous
functions of the states.
Assumption 1. If the generated inflammatory doses up and ua and the initial states
are non-negative (i.e. up(t) ≥ 0, ua(t) ≥ 0 ∀t and P (0) ≥ 0, N(0) ≥ 0, D(0) ≥
0, Ca(0) ≥ 0) then the solution trajectories of the differential equations (1)-(4) remain
in the positive octant.
This is a reasonable assumption since the states represent biological entities that are
inherently positive.
4. Numerical solution of optimal control problem
Numerical solutions of our optimal control problem are found by applying direct opti-
mization via the use of PSOPT [30], an open source pseudospectral optimization software
package. PSOPT is written in C++ and uses direct collocation methods, including Leg-
endre or Chebyshev pseudospectral discretization as well as local transcriptions such as
the trapezoidal or Hermite-Simpson integration methods. Sparse nonlinear programming
is then used to find local optimal solutions. PSOPT can be interfaced to, IPOPT, the
open source Interior Point Optimization solver ([31]) for solving large scale optimization
problems. This solver will be used for all simulations in this work.
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A good example that highlights the relationship between nonlinear programming
(NLP) and optimal control can be found in [32], where the Karush-Kuhn-Tucker (KKT)
necessary conditions approach the necessary condition of the maximum principle as the
number of nodes increases (i.e. as the step size h → 0. The NLP Lagrange multipliers
can be interpreted as a discrete approximation of the adjoint variables found using the
maximum principle, which motivates the following remark.
Remark 4.1. Using the Lagrange multipliers provided by PSOPT, the numerical solu-
tions can be verified by showing that they satisfy the necessary conditions of optimality
with good accuracy.
We observed that the Hermite-Simpson integration method provided better conver-
gence results and accuracy (O(h4)) ([30]), when compared to either trapezoidal methods
provided in PSOPT which are known to have an accuracy of O(h2). The Pseudospectral
discretization method of Legendre or Chebyshev proved to be slow to converge and not
accurate although these have been successfully applied elsewhere (e.g., [33], [34]). In ad-
dition, since we found that the solution of the optimal control problem of the previously
mentioned two patients to be very similar, we will focus on providing simulation results
related to the patient with a septic outcome.
We note that the control objectives in this work are to minimize the levels of pathogen
and of damage such that P = 0 and D = 0, respectively, while at the same time making
sure to use the lowest possible dosing amounts. In addition, we make the following
assumption
Assumption 2. If the generated inflammatory doses up and ua and the initial states are
positive semidefinite (i.e. up(t) ≥ 0, ua(t) ≥ 0 ∀t and P (0) ≥ 0, N(0) ≥ 0, D(0) ≥
0, Ca(0) ≥ 0) then the solution trajectories of the differential equations (1)-(4) remain
in the positive octant.
A number of grid points N = 1000 is used together with a tolerance of 10−6 for the
NLP solver specifications. All simulations are performed for a week (168hours) and,
therefore, the sampling period, given the number of grid points, is every 0.168 hours.
For each simulation we report the cost function Jz, where z specifies the corresponding
subsection in which the particular cost function is defined; the entry and exit times, t1
and t2, respectively, of the singular arc, if one exists in the case where an L
1 type objective
function is used; and the numerical value of the states, P , N , D, and Ca at the final time,
tf . Note that in all the control simulations it can be verified that by further integrating
the system from the final state x(tf ) the virtual patient will eventually converge to its
healthy equilibrium. In the next section we will formulate the optimal control problem
with an L1 type objective and define the necessary optimality condition of the maximum
principle related to problem given in (7).
4.1. Optimal Control with L1 type Objective
We now formulate the optimal control problem with an L1 type objective and define
the necessary optimality conditions of Pontraygin’s maximum principle. The L1-type
objective function has the following form:
JL1 = x(tf ) +
∫ tf
0
[
Ax(t) +Bu(t)
]
dt, (9)
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where x = [x1, x2, x3, x4]
T and where A = [a1, a2, a3, a4] together with B = [b1, b2]
are row vectors with positive constants. Also, x(t) = [P (t), N(t), D(t), Ca]
T ≥ 0 and
u(t) = [up, ua]
T ≥ 0, where ≥ means componentwise.
To ensure that the lowest possible dosing amounts are used to achieve the objective,
we include the input doses, up and ua, in the cost function JL1 above. The mediators
N and Ca are also included in the cost function since the steady state for these values
in healthy patients is assumed to be very low for Ca and zero for N . This inclusion will
ensure to keep the level of inflammatory mediators at lower values. It was also noticed
that the optimal control solver converges faster in the presence of N and Ca in the cost
function.2
Remark 4.2. Note that the existence of optimal controls with state constraints are more
difficult but can be obtained when variations can be done within the admissible set of con-
trols. For background on problems with state constraints and the corresponding necessary
conditions, see [35, 36]
The consequence of using an objective that is linear in the controls is that the resulting
time-varying controls will be “bang-bang”, meaning that treatment protocols alternate
between the maximum dose of pro- and/or anti-inflammatory therapies and the minimum
(i.e. zero) dose. Singular controls may also arise and will be discussed later. Since we
are minimizing the cost of JL1 , the standard Hamiltonian is given by:
H(x, u, λ) = Ax(t) +Bu(t) + λ(t)T (f(x) + g(x)u(t)), λ ∈ R4. (10)
In what follows, we characterize the optimal control which is then illustrated in several
simulations where we explore various constraints on the dosing controls as well as mixed
state-control constraints.
Theorem 1. (Characterization of the optimal control) Given two optimal controls u∗p,
u∗a with the corresponding solutions P
∗, N∗, D∗, C∗a of the ordinary differential equation
given in Eq.(1)-Eq.(4), there exist adjoint equations associated with the system states
2The necessary inclusion here of N and Ca in the objective function differs from that used in our
previous studies using MPC ([12], [13]).
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given by
λ˙1 = −a1 − λ1
[
a− 2bP − c
d+ eP
+
ceP
(d+ eP )2
− zN
g + C2a
]
− λ2
[ h(nC2a + o)
(nC2a + kP + lN +mD + o)
2
]
; (11)
λ˙2 = −a2 − λ1
(
zP
g + C2a
)
− λ2
[ i(nC2a + o)
(nC2a + kP + lN +mD + o)
2
− p
]
− λ3
[ 6qtN11
((sC2a + r)
6 + tN6)2
]
− λ4
[ u(g + C2a)
(g + C2a + wD + gN)
2
]
;
λ˙3 = −a3 − λ2
[ j(nC2a + o)
(nC2a + kP + lN +mD + o)
2
]
+ λ3kd − λ4
[ v(g + C4a)
(g + wD +N)2
]
; (12)
λ˙4 = −a4 − 2λ1 zPNCa
(g + C2a)
2
+ λ2
[ 2nCa(hP + iN + jD)
(nC2a + kP + lN +mD + o)
2
]
+λ3
[ 12qsN6(sC2a + r)5
((sC2a + r)
6 + tN6)2
]
− λ4
[ 2(uN + vD)Ca
(gN + wD + C2a + g)
2
− kc
]
; (13)
and satisfying the following transversality condition
λ(tf ) =
{∂φ[x(tf )]
∂x
}
= 1. (14)
Furthermore,
u∗p =
{
0 if b1 + λ2 > 0
Nmax if b1 + λ2 < 0
(15)
u∗a =
{
0 if b2 + λ4 > 0
Camax if b2 + λ4 < 0
(16)
Proof. The adjoint equations and the transversality conditions follow from Pontryagin’s
maximum principle [21]. Differentiating the negative of the Hamiltonian with respect to
the states, P , N , D, and Ca, gives the adjoint system in Eq.(11)-(13). According to the
maximum principle, the optimality equations are then given by
∂H
∂up
= b1 + λ2 = 0 (17)
∂H
∂ua
= b2 + λ4 = 0. (18)
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These are known as switching functions and if we denote them by
φ1(t) = b1 + λ2 and (19)
φ2(t) = b2 + λ4, (20)
then the optimal control that minimizes the Hamiltonian becomes
u∗p =
{
0 if φ1(t) > 0
Nmax if φ1(t) < 0
(21)
u∗a =
{
0 if φ2(t) > 0
Camax if φ2(t) < 0.
(22)
As was done in our previous studies, we define Nmax = 0.5 and Camax = 0.62 as
the maximum allowed levels of the variables N and Ca, respectively. This restriction is
to emulate a realistic bound appropriate in a clinical setting to avoid toxicity effects of
potential overdosing. As will be seen, these maximum bounds are violated when state
constraints are not included in the problem statement. We next provide several numeri-
cal solutions to the optimal control problem with the L1 type objective and discuss issues
regarding when singular controls arise as well as the case necessitating an explicit inclu-
sion of state constraints. The following weights appearing in the objective function 9 for
the L1 case will be used for the various constraint scenarios explored: (b1, b2) = (1, 50)
and (a1, a2, a3, a4) = (100, 5, 30, 10). The largest weights are assigned to the states P
and D since eliminating the pathogen and decreasing the level of damage is our goal.
4.1.1. Numerical results for L1 objective with dosing constraints 0 ≤ up ≤ 0.5 and
0 ≤ ua ≤ 0.62
In this scenario we assume the upper bounds on the dosing input to be the same
as those used in [12]: 0 ≤ up ≤ 0.5 and 0 ≤ ua ≤ 0.62. Figure 3 displays the sim-
ulation results of this scenarios, showing the optimal states of Pathogen (P ), the pro-
inflammatory state (N), the level of Damage (D) and the anti-inflammatory state (Ca)
in Figure 3 (a)-(d) and the resulting control doses, up and ua, in panels (e)-(f). The
pro-inflammatory control up is provided at maximum level for about half an hour, while
the anti-inflammatory dose ua is followed just after for about one hour. Although not
very evident in Figure 3, ua is applied with one sample difference after up.
When a switching function is not zero there is “bang-bang” control and, although
the controls are “bang-bang” for most of the simulation, ua actually portrays a singular
control between time (t1, t2) = (2.354, 23.88). The scaled switching function φ2 shown
in Figure 3(h) is zero during this interval, unlike φ1 in panel (g) which does not vanish
in any finite open interval. We first demonstrate that the singular control is minimizing
and then demonstrate that an approximation to the singular control gives similar results
and provides a more practical dosing protocol to implement.
To determine if the singular control generated is minimizing, we derive a solution cor-
responding to the singular control. However, the fact that there is no explicit dependence
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Figure 3: (a)-(d) Time courses for optimal states, (e)-(f) control states, and (g)-(h) the switching
functions φ1 and φ2. Control constraints in this simulation which uses an L1 type objective are 0 ≤
up ≤ 0.5, 0 ≤ ua ≤ 0.62.
on the control in either switching function (19) or (20) makes it problematic to determine
where they vanish and higher order derivatives must be examined in order to derive a
solution that will correspond to the singular control. As mentioned, singular control oc-
curs in the anti-inflammatory control ua and thus, the switching function corresponding
to φ2 will be of interest. The first derivative of φ2 is given in Eq.(23); however, since the
control does not appear in the expression, a second derivative is needed.3
φ˙2 = −a4 − 2λ1 zPNCa
(g + C2a)
2
+ λ2
[ 2nCa(hP + iN + jD)
(nC2a + kP + lN +mD + o)
2
]
+λ3
[ 12qsN6(sC2a + r)5
((sC2a + r)
6 + tN6)2
]
− λ4
[
− 2(uN + vD)Ca
(gN + wD + C2a + g)
2
− kc
]
= 0 (23)
3If φ2 vanishes on (t1 , t2) then we must have φ2 = φ˙2 = φ¨2 = 0 until the first control appears
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The second derivative of φ2 is given by Equation (24) where the control now appears,
and which φ2 = 0 can be solved to derive the solution corresponding to the singular
control.
φ¨2 =
(
−2λ1zNCa
(C2a + g)
2
− 2b1nCah
(nC2a + kP + lN +mD + o)
2
+
4b1nCa(hP + iN + jD)k
(nC2a + kP + lN +mD + o)
3
)
P˙
+ θ1
(
(hP + iN + jD)
(nC2a + kP + lN +mD + o)
− pN
)
+
[ −2b1nCaj
(nC2a + kP + lN +mD + o)
2
+
4b1nCa(hP + iN + jD)m
(nC2a + kP + lN +mD + o)
3
+ b2
(
2vCa
(gN + wD + C2a + g)
2
− 2(2uN + 2vD)Caw
(gN + wD + C2a + g)
3
)]
D˙
+ θ2
(
sc+ (uN + vD)
(gN + wD + C2a + g)
− kcCa
)
− 2λ˙1 zPNCa
(g + C2a)
2
+ λ˙2
[ 2nCa(hP + iN + jD)
(nC2a + kP + lN +mD + o)
2
]
+ θ1up + θ2ua = 0, (24)
where
θ1 = −2 λ1zPCa
(C2a + g)
2
− 2b1niCa
(nC2a + kP + lN +mD + o)
2
+
4b1nCa(hP + iN + jD)l
(nC2a + kP + lN +mD + o)
3
+
72qsN5(sC2a + r)
5
((sC2a + r)
6 + tN6)2
λ3 − 144λ3qsN
11(sC2a + r)
5t
((sC2a + r)
6 + tN6)3
+ b2
(
2uCa
(gN + wD + C2a + g)
2
− 2(2uN + 2vD))Cag
(gN + wD + C2a + g)
3
)
(25)
and
θ2 = 8
λ1zPNC
2
a
(C2a + g)
3
− 2 λ1fPN
(C2a + g)
2
− 8 λ2(hP + iN + jD)n
2C2a
(nC2a + kP + lN +mD + o)
3
+ 2
λ2(hP + iN + jD)n
(nC2a + kP + lN +mD + o)
2
+ 120λ3
qs2N6(sC2a + r)
4Ca
((sC2a + r)
6 + tN6)2
− λ4
( −(2uN + 2vD)
(gN + wD + C2a + g)
2
+
(4(2uN + 2vD))C2a
(gN + w ∗D + C2a + g)3
)
− 288λ3 qs
2N6(sC2a + r)
10Ca
((sC2a + r)
6 + tN6)3
.
(26)
For singular control to be minimizing, the generalized Legendre-Clebsch condition
shown in (27) needs to be satisfied [37].
(−1) ∂
∂ua
d2
dt2
∂H
∂ua
≥ 0 (27)
That is, during the simulation, the expression in −θ2 (See Figure 3(h)) must be pos-
itive semi-definite. Although not reported here, a plot of −θ2 (See Eq.(26)) shows that
it is strictly positive for t ∈ (t1, t2), where t1 = 2.354 and t2 = 23.88, proving the opti-
mality of the singular arc. If we consider the pro-inflammatory input, up, to be constant
then the singular control part of ua can be easily derived from Eq.(24). Note that in all
simulations, up is zero during the interval where a singular control is present in ua.
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Figure 3(a)-(f) displays results of the simulation. The cost function J4.1.1 associated
with Figure 3, the entry and exit times of the singular control, and the final states
corresponding to the simulation are given as follows:
J4.1.1 = 2104.78 t1 = 2.354 t2 = 23.88
P (tf ) = 0 N(tf ) = 0.0061 D(tf ) = 0.025
Ca(tf ) = 0.29
Finally, we consider an approximation to the “bang-bang-singular” control (or what
we term the basic optimal control), where we replace the time course for the singular
control with a constant input, namely zero. In other words, we do not provide any
dosing of ua during the period where the singular control occurred and determine if
this approximation is acceptable in terms of the resulting outcomes of the states. The
motivation of replacing the singular control with a constant is to suggest a more practical
implementation of the dosing protocol.
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Figure 4: Comparison of basic optimal control with an approximate control for the L1 objective case
with dosing constraints of 0 ≤ up ≤ 0.5 and 0 ≤ ua ≤ 0.62. (a) Generated optimal controls up and ua
and (b) corresponding optimal states. (c) Generated optimal control up and approximation of optimal
control ua and (d) corresponding states. The time frame displayed in both plots (a) and (c) of the
control doses is for tf = 40 hours since afterward the values of both controls are zero.
Figure 4 provides the comparison of the simulation using the optimal controls gener-
ated for up and ua (panels (a)-(b) which are the same as in Figure 3(a)-(f)) versus the
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simulation where an approximation of the ua control was made for the singular arc (pan-
els (c)-(d)). Comparison of Figure 4 panel (d) with (b) shows that the states Ca and D
are the ones mainly affected by this approximate control case. In other words, changing
the level of anti-inflammatory dose Ca, namely reducing it to zero for that time period,
has a direct impact on the mitigation of damage (D). Thus, a lack of anti-inflammatory
mediator at critical moments results in an increase of the level of damage, which is seen
in Figure 4(d). In this particular case, the long-term dynamics of the two simulations are
the same; however, such approximations would need to be done carefully. An improved
solution might be to approximate the singular arc by a piece-wise constant function of
say, four pieces which would better capture the gradual decrease of ua occurring in the
singular arc.
4.1.2. Numerical results for L1 objective with dosing constraints 0 ≤ up ≤ 0.25 and
0 ≤ ua ≤ 0.31
We next explored how a reduction of the maximum allowable doses affected the ability
of the control problem with L1 objective to drive the patient to its healthy state. Thus
the upper bounds on up and ua were reduced to 0 ≤ up ≤ 0.25 and 0 ≤ ua ≤ 0.31, which
is half of the amount used in the previous section. The resulting simulation is given in
Figure 5 (a)-(b). The numerical information about the cost, exit and entry times for the
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Figure 5: Comparison of basic optimal control with an approximate control for the L1 objective case
with upper bounds on dosing constraints given as upmax = 0.25 and uamax = 0.31. (a) Generated
optimal controls up and ua and (b) corresponding optimal states. (c) Generated optimal control up and
approximation of optimal control ua and (d) corresponding states. The time frame displayed in both
plots (a) and (c) of the control doses is for tf = 40 hours since afterward the values of both controls are
zero.
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singular arc, as well as the final states corresponding to Figure 5 are given by
J4.1.2 = 2469.904 t1 = 3.363 t2 = 21.02
P (tf ) = 0 N(tf ) = 0.0074 D(tf ) = 0.0326
Ca(tf ) = 0.311
The singular control verifies the Legendre-Clebsch condition in (27) for optimality. The
simulation results show an increase in the cost function J4.1.2 when compared to J4.1.1 of
the previous section and this can be explained by the increase of the level of Damage, D,
as a result of decreasing the total dose of the anti-inflammatory mediator, Ca. Similar
to what was done in the previous section, Figure 5 (d) displays the outcome of the states
when an approximation of the optimal control input, ua, is made as shown in panel (c).
In either sets of simulations for this and previous section and in either the optimal
or approximate cases, we observe that the level of damage (D) remains such that D ≤ 1
(and can be verified to approach zero eventually in the absence of further control) and
the level of pathogen (P ) decreases relatively quickly to zero. An interesting pattern we
observe is that each dose associated with an increase of the pro-inflammatory mediator
is followed immediately after by a dose of anti-inflammatory therapy. This behavior can
be explained by the fact that the immune system requires an initial boost of activated
phagocytes, N , to eliminate the pathogen threat, but the resulting inflammation causes
some self-harm seen in the relative increase of tissue damage, D, which then needs the
inhibitory effects of CA via an anti-inflammatory dose, ua, to ensure the decay of damage.
The anti-inflammatory dosing input is applied for a period of time clearly longer than
up. It is interesting to notice in Figure 5 that when the maximum allowable doses were
decreased by half, the control doses seems to be applied for a longer duration when com-
pared to the initial scenario where Nmax = 0.5 and Camax = 0.62. As a consequence of
lowering the intensity of the dose, the optimal control compensates by allowing a longer
application. This behavior was also observed when solving the TPBVP for the L1 prob-
lem using the forward backward sweep method in [22].
It can also be seen in Figure 4 of the previous section that the anti-inflammatory states
do not remain below the upper bound mentioned previously on the anti-inflammatory
state Ca (i.e. Camax = 0.62
4) and the same is used for the simulations of this section
given in Figure 5, even though the maximum upper bound on the doses for both controls
was reduced by half. Thus, in the next section, we impose state constraints on N and
Ca in the problem formulation.
4The max value for Ca was derived from the bifurcation study in [19] of the N/D subsystem. It was
determined in that study that the system loses bi-stability between the healthy and the death state if
Ca > 0.62 with only the healthy state being stable. For this reason, to ensure the presence of a stable
death state the latter bound on Ca is enforced. The max value of N = 0.5 was determined experimentally
(through simulations; See [12])
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4.1.3. Numerical results for L1 objective with state and dosing constraints
In this section, we now impose the state constraints on N and Ca we defined earlier
of 0 ≤ N(t) ≤ 0.5 and 0 ≤ Ca ≤ 0.62, along with dosing constraints of 0 ≤ up ≤ 0.5 and
0 ≤ ua ≤ 0.62 which are the same dosing constraints of Section 4.1.2. The analysis of the
numerical results obtained when using the state constraints together with the control
constraints would be subject, in most part, to the same discussion as in the section
before; the only difference would be the additional jump conditions on the adjoints and
the transversality condition. To be more pertinent, we will refer the reader to the similar
discussion presented later in section 4.2.2. For the sake of brevity, the details are not
provided for this case.
The resulting simulation is given in Figure 6 and the numerical information about
the costs and final states corresponding to Figure 6 are given by
J4.1.3 = 2393.339 t1 = 2.186 t2 = 4.036
P (tf ) = 0.0000 N(tf ) = 0.0073 D(tf ) = 0.0318
Ca(tf ) = 0.3093
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Figure 6: Optimal doses and corresponding state trajectories for an L1 type objective with state
constraints 0 ≤ N(t) ≤ 0.5, 0 ≤ Ca ≤ 0.62 together with dosing constraints 0 ≤ up ≤ 0.5 and
0 ≤ ua ≤ 0.62. (a) Dosing profiles for up and ua controls that lead to (b) a healthy outcome as all states
decrease toward background levels. The time frame displayed in (a) of the control doses is for tf = 40
hours since afterward the values of both controls are zero.
The simulation in Figure 6(a) shows that a singular arc occurs between time t1 = 2.186
and t2 = 4.036, which can be verified as before by checking the resulting function φ2,
as the one given in Figure 3(h). The optimality of the singular arc can be derived by
verifying the Legendre-Clebsh condition of (27). Notice that 6(a) shows that the pro-
inflammatory dose is applied for a duration of almost 20 minutes followed by a rest
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period of 50 minutes before the anti-inflammatory dose is injected for a longer duration
corresponding to one hour.
Thus far, we have studied optimal control scenarios in which the objective is linear
in the control. In the remainder of this paper the focus will be on deriving the optimal
control doses subject to an objective that is quadratic in the control as well as different
constraint types. A discussion comparing the results of the uses of the different objective
functions will also be given.
4.2. Optimal Control with L2 type Objective
In this section we present numerical simulations of the optimal control problem when
the objective is quadratic in the control.
JL2 = x
T (tf )x(tf ) +
∫ tf
0
[
x(t)TAx(t) + u(t)TBu(t)
]
dt (28)
where A and B are matrices with diagonals (a1, a2, a3, a4) and B = (b1, b2) respectively.
Also, x(t) = [P (t), N(t), D(t), Ca]
T ≥ 0 and u(t) = [up, ua]T ≥ 0, where ≥ means com-
ponentwise.
We also once again define Nmax = 0.5 and Camax = 0.62 as the maximum allowed
levels of the variables N and Ca, respectively. We provide several numerical solutions
to the optimal control problem with the L2 type objective under various constraint def-
initions. The following weights appearing in the objective function (28) for the L2 case
will be used for the various constraint scenarios explored in the subsections that follow:
(b1, b2) = (1, 20) and (a1, a2, a3, a4) = (10, 1, 10, 10). Note that the objective function
includes the cost at the final time, φ(x(tf )
2). All other aspects of the numerical settings
are as given in the beginning of Section 4.
The Hamiltonian for the L2 type objective is given according to
H(x, u, λ) = x(t)
T
Ax(t) + u(t)
T
Bu(t) + λ(t)T (f(x) + g(x)u) (29)
where λ(t) = (λ1, λ2, λ3, λ4)
T . While The L1 type objective leads in general to more
intricate analysis involving bang-bang and singular control, the L2 type objective analysis
often results in continuous control, when no state constraints are included. The case of
mixed state-control inequality constraint will be introduced in next section, followed by
a section that looks at separate or pure control and state constraints. For all constraints
used in the following subsections, those associated with N and/or up have a maximum
bound of 0.5, while those associated with Ca and/or ua have a maximum bound of 0.62.
4.2.1. Numerical results for L2 objective with mixed control-state inequality constraints
Consider the mixed control-state inequality constraints 5 given according to
C1(N(t), up(t)) = up(t) +N(t)− 0.5 ≤ 0 (30)
C2(Ca(t), ua(t)) = ua(t) + Ca(t)− 0.62 ≤ 0. (31)
5Note that we adhere to the sign convention in [23]
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Imposing mixed control-sate constraints allows the derived optimal control to account
for the actual value of the states, and hence only the necessary control dose will be
administered. The simulation results for this OCP are given in Figure 7 and correspond
to the numerical information about the costs and final states given as follows:
J4.2.1 = 602.67 P (tf ) = 0 N(tf ) = 0.0082 D(tf ) = 0.0376 Ca(tf ) = 0.3216 (32)
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Figure 7: (a) Optimal doses and (b) corresponding state trajectories for a quadratic type objective with
mixed control state inequality constraints 0 ≤ up(t) ≤ 0.5 −N(t), 0 ≤ ua(t) ≤ 0.62 − Ca(t). The time
frame displayed in (a) of the control doses is for tf = 40 hours since afterward the values of both controls
are zero.
Note that both controls are constrained to be positive semidefinite, i.e., 0 ≤ up
and 0 ≤ ua. All the constraints are adjoined such that the augmented Hamiltonian in
equation (29) can be expressed according to
H(x, u, λ, µ) = H(x, u, λ) + µ1C1(N, up) + µ2C2(Ca, ua)− µ3up − µ4ua. (33)
Necessary conditions for minimizing the Hamiltonian can then be derived. The multiplier
µ is given such that it verifies the complementary condition
µi =
{
0 if Ci < 0
µi ≥ 0 if Ci = 0 for i = 1, 2.
(34)
The adjoint equations are given in the following compact form
λT = −Hx =
{
−Hx(x, u, λ) if C < 0
−Hx(x, u, λ)− µCx if C = 0;
(35)
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and more explicitly as follows:
λ˙1 = −∂H
∂P
λ˙3 = −∂H
∂D
(36)
λ˙2 = −∂H
∂N
− µ1 λ˙4 = − ∂H
∂Ca
− µ2. (37)
The controls up or ua can be derived from the mixed constraints along the constrained
arc. In other words, whenever
C(x, u) = 0 for t ∈ (t1, t2). (38)
Hence, the boundary controls are given by
upb = 0.5−N(t) (39)
uab = 0.62− Ca(t). (40)
The free controls can be derived from the minimum condition such that
up = − λ2
2b1
(41)
ua = − λ4
2b2
. (42)
Since the regularity condition is verified, i.e., Cu(x, u) 6= 0, the multiplier µ follows from
the local minimum condition µ = µ(x, λ) = −Hu(x, λ, ub(x))/Cu(x, ub(x)). In other
words, by
µ1 = −2b1up − λ2 (43)
µ2 = −2b2ua − λ4, (44)
whenever the lower constraints on the controls are not active (i.e. up > 0 and ua > 0).
When the mixed constraints are active, the multipliers µ1 and µ2 are given by substituting
the equation for upb given in (39) into (43) and similarly for uab of (40) into (44), such
that
µ1 = −2b1(0.5−N(t))− λ2 (45)
µ2 = −2b2(0.62− Ca(t))− λ4. (46)
The optimal controls are given as follows
up(t) =
{
− 12b1 (λ2 + µ1) if 0 ≤ t ≤ t0 = 1.009
0 if t0 ≤ t ≤ tf = 168;
(47)
ua(t) =

0, if 0 ≤ t ≤ t1 = 1.009
−1
2b2
(λ4 + µ2), if t1 ≤ t ≤ t2 = 19
0, if t2 ≤ t ≤ tf = 168.
(48)
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Note that the mixed control-state constraints, C1 and C2 in equations (30) and (31),
respectively, are active whenever the controls are not zero; that is, µ1 ≥ 0 and µ2 ≥ 0.
For 0 ≤ t ≤ t0 and t1 ≤ t ≤ t2 the switching structure is given by the junction conditions
µ1(t) = −2b1(0.5−N(t))− λ2(t) = 0 (49)
µ2(t) = −2b2(0.62− Ca(t))− λ4(t) = 0. (50)
The next section presents a scenario where we have pure state constraints on N and
Ca as well as constraints on the upper bounds of the control doses.
4.2.2. Numerical results for L2 objective with pure state and control constraints
Now consider imposing path constraints on the states N and Ca such that N(t) ≤ 0.5
and Ca(t) ≤ 0.62 ∀t. In addition, we will require as before that the following control
constraints be met: 0 ≤ up ≤ 0.5 and 0 ≤ ua ≤ 0.62. The simulation results for this
OCP are given in Figure 8 and correspond to the numerical information about the costs
and final states given as follows:
J4.2.2 = 513.77 P (tf ) = 0 N(tf ) = 0.0071 D(tf ) = 0.0306 Ca(tf ) = 0.3065
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Figure 8: (a) Optimal doses and (b) corresponding state trajectories for a quadratic type objective with
state path constraints 0 ≤ N(t) ≤ 0.5, 0 ≤ Ca ≤ 0.62. The time frame displayed in (a) of the control
doses is for tf = 40 hours since afterward the values of both controls are zero.
Consider the last inequality in the (OCP) problem S(x(t)) ≤ 0, given specifically for
this case as
S1(N(t)) = N(t)− 0.5 ≤ 0 (51)
S2(Ca(t)) = Ca(t)− 0.62 ≤ 0. (52)
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Whenever one of the constraints becomes active on a subinterval we have
Si(x(t)) = 0 for all t ∈ (t1, t2) ⊂ [0, 168]. (53)
Let r be the order of the state constraint; that is, the smallest non-negative numbers
necessary for the control to first appear [38]. It is straightforward to see that r = 1 and
furthermore,
S˙2(x, ua) = C˙a = sc +
uN + vD
g + C2a + gN + wD
− µcCa + ua(t). (54)
The state constraint satisfies the following regularity condition
∂
∂ua
S˙2(x, ua) = (0, 1) 6= (0, 0). (55)
Remark 4.3. We can derive similar conditions for S1. We will focus on the state Ca
since that is the only state that becomes active.
The boundary control uab on the constrained arc can be derived from (54) by also
replacing Ca(t) = 0.62 such that
uab = −sc −
uN + vD
g + 0.622 + gN + wD
+ 0.62µc. (56)
The augmented Hamiltonian is given according to
H(x, u, λ, λs) = x(t)TAx(t) + u(t)TBu(t) + λ(t)T (f(x) + g(x)u) + λsS(x), (57)
+ µ1(up(t)− 0.5) + µ2(ua(t)− 0.62)− µ3up − µ4ua, (58)
where λs = [λsp, λsa] is a row vector and S(x) = [S1, S2]
T is a column vector. The
adjoint equation can be formulated in a similar fashion as in (35). The multiplier λsa
needs to verify the complementary slackness condition [38] given as:
λsa =
{
0 if S2 < 0
λsa ≥ 0 if S2 = 0.
(59)
The adjoint equation corresponding to the dynamic equation C˙a is given by
λ˙4(t) = − ∂H
∂Ca
− λsa. (60)
The minimum condition can be derived as in the previous section when 0 = ∂H∂up =
2b2ua + λ4. On the boundary arc, ua is constant (See Figure 9), and we get λ˙4 = 0 as
can be seen in the same figure. The multipliers λsa can be derived from (60) according
to
λsa = − ∂H
∂Ca
∣∣∣∣∣
Ca=0.62
. (61)
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The optimal controls are given as follows
up(t) =
{
0.5 if 0 ≤ t ≤ t0 = 0.3363
0 if t0 ≤ t ≤ tf = 168;
(62)
ua(t) =

0, if 0 ≤ t ≤ t1 = 1.009
0.62, if t1 ≤ t ≤ t2 = 2.186
uab , if t2 ≤ t ≤ t3 = 17.32
−1
2b2
(λ4), if t3 ≤ t ≤ t4 = 17.66
0, if t4 ≤ t ≤ tf = 168.
(63)
The jump conditions and transversality condition are given, respectively, as
λ(ts−) = λ(ts+) + βsSx(x(ts)) βs ≥ 0 and (64)
λ(tf ) = (2P (tf ), 2N(tf ), 2D(tf ), 2Ca(tf )). (65)
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Figure 9: Numerical solutions of the state and control constrained problem with L2 objective. Top
row: control ua(t) and constrained anti-inflammatory state Ca(t). Bottom row: The scaled adjoint
λ4 corresponding to the state Ca(t) together with the multiplier λsa corresponding to the constraint
S(x(t)) = Ca(t)− 0.62. The time frame displayed in the figures is for tf = 40 hours since afterward the
values of the control inputs are zero.
Figure 9 displays the computed anti-inflammatory dose ua and the evolution of the
constrained state Ca together with the adjoint variable λ4 and the multiplier λs corre-
sponding to the state constraint S(x(t)) = Ca(t) − 0.62. The Figure outlines that the
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constraint on Ca becomes active in the interval [2.186, 17.32]. One can also see in the
same figure that the multiplier λs satisfies the complementary condition (59). The jump
discontinuity at t1 = 2.186 on the control ua for this L
2 optimal control is nonintuitive
since one would expect a continuous control as in the scenario of the previous section;
however, this result is common when using pure state constraints (See Eq. (64)). The
scaled adjoint variable λ4 in Figure 9, which is associated with the differential equation
x˙4, has a jump discontinuity at the time the constraint becomes active.
Remark 4.4. The objective functional value corresponding to section 4.2.1, which is
associated with the mixed control-state constraints is higher than the one given in section
4.2.2, that is associated with pure control and state constraints. In the case that imposes
mixed control-state inequality constraints, the maximum allowed doses are updated based
on the the actual states of Ca and N . For instance, if at a sampling time, t, Ca(t) = 0.62
the upper bound on ua is zero and similarly, if N(t) = 0.5, then the upper bound on up is
zero. However, this constraint formulation is more restrictive with the amount of doses
given which results in an increase in the damage response (Figure 7) compared with the
pure state and control constraints (Figure 8), which may require additional or longer
dosing to achieve a successful outcome.
5. Conclusion
In this work, we determined successful treatment protocols to regulate the inflamma-
tory response modeled with an ordinary differential equations system through solving the
optimal control problem using a direct approach. Two cases were considered regarding
the form of the objective functional: linear versus quadratic in the control. The results
of the direct numerical methods used are in agreement with the characterization of the
optimal control. A noticeable difference was not observed in the way the controls are
provided when considering an L1 versus L2 type objective. In either case, it was observed
that state constraints needed to be included explicitly in order for the states not to exceed
the prescribed bounds set for realistic considerations. The case where singular control
appears is also addressed when the objective is linear in the control, the optimality of
the singular arcs was demonstrated by verifying the Legendre-Clebsch condition.
The dynamics of inflammatory immune response is more complex and varied than
represented by the reduced inflammatory model considered in this study, however the
obtained computational results can provide insight into possible treatment strategies
and the methods could prove to be useful tools to incorporate in future practice. In
particular, one can see a prevailing pattern in the way the doses are implemented in
this study and is in agreement with results of previous computational studies ([12], [13]).
Whether considering the solution for the L2 or L1 type objective, generally speaking, a
successful control strategy is marked by an initial bolus of a pro-inflammatory control
(up) administered first to quickly eliminate the harmful effect of the pathogen, followed
just after by a two phase application of the anti-inflammatory mediator (ua). In the first
phase, a bolus of anti-inflammation is applied, followed by a longer duration application
of ua, but with a very small amount. The similar patterns in the generated control
doses up and ua when solving for either type of objective seems clinically reasonable
when thinking that in the presence of a pathogen, the pro-inflammatory mediators will
naturally increase to try to eliminate the pathogen, which in turn will cause a certain
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increase in the level of collateral tissue damage which incites further inflammation. If
not controlled, this positive feedback may result in the death of the patient. Fortunately,
however, the response also includes a release of anti-inflammatory mediators which helps
alleviate the harmful effect of the pro-inflammation, ultimately driving the patient to
its healthy equilibrium in the absence of further pathogen threat. So essentially, the
dynamic necessary for stabilizing a patient with sever inflammation is reflected exactly
by increasing the pro-inflammatory effects with input up followed just after by a dose of
anti-inflammatory mediator, with input ua. It is important to notice in our study that we
assume the dosages represent the actual concentrations with idealized effect on patient;
that is, we do not assume any model for the pharmacokinetics or pharmacodynamics.
The effects of these two phenomena on optimal protocols could be included in further
study. Future work would also benefit from the use of an immune response model that
displays similar complex behavior as the reduced model but does not lump too many
variables together to see how the obtained results would then relate to what has been
presented in this work.
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